5 November 2020 - Following the launch of its Biosimilars Initiative in December 2019, Alberta, Canada, has succeeded in switching 16% of patients from use of 7 reference products to approved biosimilar versions.

Alberta’s switching program launched 6 months after British Columbia began a similar initiative, which is further ahead with converting patients to biosimilars.

Read Center for Biosimilars article